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Abstract: Changes in protein glycosylation are related to different diseases and have a potential as diagnostic and prognostic disease 
biomarkers. Transferrin (Tf) glycosylation changes are common marker for congenital disorders of glycosylation. However, biological 
interindividual variability of Tf N-glycosylation and genes involved in glycosylation regulation are not known. Therefore, high-throughput Tf 
isolation method and large scale glycosylation studies are needed in order to address these questions. Due to their unique chromatographic 
properties, the use of chromatographic monoliths enables very fast analysis cycle, thus significantly increasing sample preparation throughput. 
Here, we are describing characterization of novel immunoaffinity-based monolithic columns in a 96-well plate format for specific high-
throughput purification of human Tf from blood plasma. We optimized the isolation and glycan preparation procedure for subsequent ultra 
performance liquid chromatography (UPLC) analysis of Tf N-glycosylation and managed to increase the sensitivity for approximately three times 
compared to initial experimental conditions, with very good reproducibility. 
 





LYCOSYLATION is a co-translational and post-transla-
tional modification of proteins by attachment of 
sugar moieties (glycans). It not only affects the glycoprotein 
structure, but also proper folding and consequently 
glycoprotein stability and function.[1–4] There is no direct 
„instruction“ for glycan synthesis, hence it is the result of 
the amount and activity of glycosyl transferases, 
glycosidases, enzymes involved in sugar precursors 
synthesis, sugar transporters, and amount of sugar 
precursors.[5] Glycosylation is involved in essential cell 
processes including signalization, interaction and 
recognition of cells.[6] Therefore, it is not strange that 
changes in glycosylation patterns are related to congenital 
disorders of glycosylation,[7–9] cancer,[10] different auto-
immune[11] and inflammatory diseases[12] and have a high 
potential as diagnostic and prognostic disease bio-
markers.[13] To meet the demand of determining normal 
and aberrant biological glycosylation patterns of individual 
and total glycoproteins from body fluids and tissues in 
different human populations, methods for glycan analysis 
of large number of samples (so called high-throughput 
methods) are being extensively developed in recent 
years.[14–17] 
 Transferrin (Tf) is a glycoprotein that transports iron 
to cells and in humans has two N-glycosylation sites – at 
asparagine 432 and asparagine 630. Tf N-glycans are mostly 
of biantennary complex type with terminal N-acetylneura-
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or both N-glycans is the most common marker for 
congenital disorders of glycosylation.[18] Altered Tf 
glycosylation is also reported in hepatocellular 
carcinoma[19] and chronic alcohol consumption.[20,21] 
Although some studies on N-glycosylation pattern of Tf 
have been done to this date, biological interindividual 
variability of Tf N-glycosylation and genes involved in its 
regulation, to the best of our knowledge, are not known. In 
order to answer these questions, high-throughput 
glycomics methods that will enable glycosylation analysis of 
a large number of Tf samples are currently under extensive 
development. 
 Monolithic supports have previously been used as a 
tool for high-throughput immunoglobulin G (IgG) isolation 
from human plasma.[22] In contrast to particulate supports 
where molecules are transferred by diffusion, chromato-
graphic monoliths are stationary phases cast in a single 
piece with highly interconnected large channels, enabling 
convective mass transport that results in flow independent 
chromatographic properties. Polymethacrylate monolithic 
supports have high dynamic binding capacity for large 
molecules and very low backpressure due to more than  
60 % porosity, so they are ideal for separation of large 
biomolecules, such as proteins, viruses, plasmid DNA, 
etc.[23] As such, monoliths are an ideal support for high-
throughput immunoaffinity applications.[24] 
 For Tf isolation from human plasma, an 
immunoaffinity purification method using convective 
interaction media (CIM) monolithic chromatographic 
support with immobilized anti-transferrin antibodies (@Tf) 
was performed. Oriented antibody immobilization onto 
CIM monoliths, whereby immobilization occurs via the 
antibody's carbohydrate moiety on a hydrazide or 
hydrazine-based supports, has been developed to enhance 
specificity of interaction with the antigen.[25,26] Here we 
show that polymethacrylate chromatographic monoliths 
with oriented immobilization of @Tf offer a great tool for 
the purification and enrichment of Tf from complex 
samples, such as plasma. 
 
EXPERIMENTAL 
Chemicals and Consumables 
2-Aminobenzamide (2-AB), 2-amino-2-hydroxymethyl-
propane-1,3-diol (Tris) buffer, 2-(N-morpholino)ethane 
sulfonic acid (MES), 2-picoline borane (2-PB), acetonitrile, 
dimethyl sulfoxide (DMSO), ethylene glycol, formic acid 
(FA), glycine, human transferrin, igepal CA630, sodium 
azide (NaN3), sodium periodate (NaIO4), sodium chloride 
(NaCl) and sodium hydroxide (NaOH) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Glacial acetic acid and 
ammonia solution (φ = 25 %) were purchased from Merck 
(Darmstadt, Germany). GelCode Blue staining reagent was 
purchased from Thermo Fischer (Waltham, ME, USA). 
PNGase F (10 U μL–1) was purchased from Promega 
(Madison, WI, USA). Phosphate buffered saline (PBS) was 
purchased from Lonza (Basel, Switzerland) or made in house: 
137 mmol L–1 NaCl, 2.7 mmol L–1 Na2HPO4, 9.7 mmol L–1 
KH2PO4, 2.2 mmol L–1 KCl, titrated with NaOH to pH 7.4. 
Sodium dodecyl sulfate (SDS) was purchased from 
Invitrogen (Carlsbad, CA, USA). 
 Buffer solutions were filtered through a 0.22 μm 
polyethersulfone (PES) filter (TPP, Trasadingen, 
Switzerland) or 0.2 μm Supor PES filters (Nalgene Thermo 
Fischer Scientific). Amicon Ultra-4 centrifugal filters, 
MWCO 10 kDa, were purchased from Merck Millipore 
(Billerica, MA, USA) and AcroPrep GHP filter plates from Pall 
Corporation (Ann Arbor, MI, USA). 
 Monoclonal antibodies (mAbs) for human Tf were 
produced at Faculty of Medicine, University of Rijeka, 
Rijeka, Croatia. In short, BALB / c mice were injected 
subcutaneously with the Tf protein (50 μg) in complete 
Freund’s adjuvant. Two weeks later, mice were boosted 
with the same protein in incomplete Freund’s adjuvant  
by injecting a two-thirds volume subcutaneously and a one-
third volume intraperitoneally (i.p.). After an additional  
2-week period, the sera of immunized mice were screened 
for antibody titers. The best responder was additionally 
boosted i.p. with the immunogen dissolved in PBS. Three 
days later, spleen cells were collected and, after lysis of red 
blood cells, fused with SP2 / 0 myeloma cells at a ratio of 1 : 1. 
The cells were seeded onto 96-well tissue culture plates in 
20 % RPMI 1640 medium containing hypoxanthine, 
aminopterin, and thymidine for hybridoma selection. These 
cultures were screened for antibodies reactive against Tf by 
ELISA. Positive mother wells were expanded, cloned and 
antibodies were tested for immunoprecipitation. Finally, 
@Tf clone transferin.09 was expanded and secreted mAbs 
were purified and used for immobilization. 
 CIM® Protein G column (8 mL), CIMac® hydrazide 
column, CIM® Protein G and hydrazide 96-well plates were 
produced at BIA Separations, Ajdovščina, Slovenia. 
 Pooled plasma sample from 3 apparently healthy 
male adult volunteers was used for method development 
and all optimizations. Pooled plasma was aliquoted and 
frozen at –20 °C until the day of experiment. All plasma 
samples were centrifuged for 3 minutes at 12 100 g, diluted 
with 1 × PBS, pH 7.4, just before Tf or IgG isolation, and 
filtered through 0.45 μm AcroPrep GHP filter plate using 
vacuum manifold (around 380 mm Hg, Millipore 
Corporation). 
Instruments Used in the Study 
Centrifuge miniSpin and centrifuge model 5804 with rotor 
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sample processing. Analytical high performance liquid 
chromatography (HPLC) system, consisting of two pumps 
with 10 mL min–1 pump heads and a UV detector – Smart-
line (Knauer, Berlin, Germany) was used for monolithic 
columns characterization. Epoch BioTek microplate 
spectrometer (Winooski, VT, USA) was used for measuring 
CIMac-@Tf 96-well plate flowthrough absorbance. Mini-
Protean II electrophoresis Cell (Bio-Rad, Hercules, CA, USA) 
and XCell SureLock™ Mini-Cell Electrophoresis System (Life 
Technologies, Carlsbad, CA, USA) were used for sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Vacuum centrifuge with vacuum concentrator 
Savant SC210A, refrigerated vapor trap Savant RVT400 and 
vacuum pump OFP400 (Thermo Scientific) were used for 
drying of IgG and Tf eluates. MRC Basic Peristaltic Pump PP-
X-575 with DG-2 head, 6 rollers and tubing: 1 mm i.d. × 1 mm 
wall (MRC, Cambridge, UK), vacuum manifolds (Ilmvac, 
Ilmenau, Germany and Millipore Corporation) and plate 
shaker (GFL, Burgwedel, Germany) were used during IgG 
and Tf isolation, and subsequent sample preparation for 
glycan analysis. Acquity ultra performance liquid 
chromatography (UPLC) instrument (Waters, Milford, MA, 
USA) consisting of a quaternary solvent manager, sample 
manager and a fluorescence detector was used for glycan 
analysis. 
Preparation of Columns with 
Immobilized @Tf 
Immunoaffinity chromatographic monoliths were prepared 
based on the CIMac® hydrazide columns with column 
volumes of 0.1 mL and average pore size diameter of  
1.4 μm. @Tf mAbs were first purified from serum free 
supernatant using CIM® Protein G 8 mL column. The 
supernatant was diluted with PBS (Lonza), ψ(supernatant, 
PBS) = 1 : 1, loaded onto the column at flow rate of 8 mL min–1 
and eluted with 3 column volumes of 100 mmol L–1 glycine, 
pH 2.7, at 8 mL min–1. pH of the elution fraction was 
adjusted to 7.0 with 1 mol L–1 Tris buffer, pH 9.0. 
 The mAbs were concentrated to 2 mg mL–1 and buffer 
was exchanged to 10 mmol L–1 phosphate, 100 mmol L–1 NaCl 
buffer, pH 7.2, using Amicon Ultra-4 centrifugal filter, 
MWCO 10 kDa. The dissolved mAb stock was mixed with a 
solution of 20 mmol L–1 NaIO4 in phosphate buffer at ratio 
of 1 : 1 (v / v) and thermostated for 30 min at 25 °C to achieve 
the oxidation of glycosylated moieties of the mAb to 
aldehyde functional groups. The reaction was quenched by 
addition of ethylene glycol (25 µL of ethylene glycol per mL 
of the mAb solution) to reaction mixture. Further, mAb 
solution was diluted twenty-fold with 50 mmol L–1 MES 
buffer, pH 5.2. The immobilization solution containing 1 mg 
of dissolved mAbs was pumped through a preconditioned 
CIMac® hydrazide column at 0.5 mL min–1. The column was 
closed with blind stoppers and thermostated for 15 hours at 
25 °C. Prepared column was finally washed with 50 mmol L–1 
MES, 1 mol L–1 NaCl solution, pH 5.2 and stored in PBS, pH 
7.2, 0.2 g L–1 NaN3. 
Preparation of 96-Well Plate with 
Immobilized @Tf 
@Tf mAb for 96-well plates was purified and treated with 
NaIO4 as described above. Subsequently, 0.5 mg of the mAb 
per well of the CIM® hydrazide plate (200 µL monolith with 
average pore size diameter of 2.1 μm) was loaded using a 
vacuum manifold (Ilmvac). The flowthrough solution was 
re-pumped through the plate 10 times during 24 h cycle. 
Finally, each well of the plate was washed with 50 mmol L–1 
MES, 1 mol L–1 NaCl solution, pH 5.2 and stored in PBS, pH 
7.2, 0.2 g L–1 NaN3. 
Specificity of Immunoaffinity Monoliths 
for Tf 
Plasma sample was prepared as described in Chemicals and 
consumables. Selectivity of prepared @Tf immunoaffinity 
monoliths was tested by bind-elute mode using the 
analytical HPLC system and EuroChrom 2000 software 
(Knauer). In short, plasma sample diluted with PBS, 
ψ(sample, PBS) = 1 : 9, was injected onto the CIMac-@Tf 
column at 1.0 mL min–1. The column was washed with PBS 
and Tf was eluted with 0.1 mol L–1 formic acid, pH 2.4. 
Flowthrough and elution fractions were collected when 
UV280 absorbance peak was detected, and analyzed by SDS-
PAGE. Undiluted elution fractions were loaded onto 4–20 % 
gradient gels under reducing conditions according to the 
manufacturer's instructions (Bio-Rad). Gels were run at 200 V 
for 35 min using a discontinuous Tris-glycine buffering 
system. Protein bands were visualized by GelCode Blue 
staining reagent. 
Determination of Dynamic Binding 
Capacity for Tf 
Dynamic binding capacity (DBC) was determined for CIMac-
@Tf column with frontal analysis experiments using the 
analytical HPLC system. Tf was dissolved in PBS (γ =  
0.05 mg mL–1), and loaded on the CIMac-@Tf column at  
1.0 mL min–1 until the point of breakthrough. The dynamic 
binding capacity at 50 % breakthrough (DBC50) was 
calculated from t50 % at which UV280 was half-maximal 
according to the [Eq. (1)]: 
 







  (1) 
 
where Φ represents the flow rate (mL min–1), t50 % is the 
time when the absorbance reached the 50 % of the break-
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γ0 is the initial protein concentration (mg mL–1) and Vc is the 
total monolith volume. 
 The DBC for CIMac-@Tf 96-well plate was 
determined using a vacuum manifold instead of the HPLC 
system to pump the solutions through the monolith. 
Aliquotes of 500 µL Tf in PBS (γ = 0.1 mg mL–1) were 
repeatedly added and plate flowthrough absorbance 
measured. The elution was performed by the addition of  
1 mL of 0.1 mol L–1 formic acid to each well. Elution 
fractions were collected and absorbance at 280 nm was 
measured. 
IgG Removal from Plasma Samples 
IgG was removed from blood plasma samples by CIM® 
Protein G 96-well plate, using vacuum manifold (Millipore 
Corporation). All steps during the isolation procedure were 
performed at around 380 mm Hg, except for plasma sample 
application and IgG elution (around 200 mm Hg). Protein G 
plate was washed with 2 mL of ultra-pure water (18 MΩ cm 
at 25 °C), 2 mL of 1 × PBS, pH 7.4, and 1 mL of 0.1 mol L–1 
formic acid; neutralized with 2 mL of 10 × PBS; and 
equilibrated with 4 mL of 1 × PBS, pH 7.4. 
 Plasma samples, ψ(sample, 1 × PBS, pH 7.4) = 1 : 7, 
were applied to the CIM® Protein G plate, and flowthrough 
was collected for subsequent Tf isolation. Unbound pro-
teins were washed away with 3 × 2 mL of 1 × PBS, pH 7.4. 
Bound IgG was eluted with 1 mL of 0.1 mol L–1 formic acid 
and neutralized with 1 mol L–1 ammonium hydrogencar-
bonate to pH 7.0. 
 The CIM® Protein G plate was washed with 1 mL of 
0.1 mol L–1 formic acid, 2 mL of 10 × PBS, 4 mL of 1 × PBS, 
pH 7.4, 2 mL of storage buffer (ethanol φ = 20 %, 20 mmol 
L–1 Tris, 0.1 mol L–1 NaCl, titrated with HCl to pH 7.4), and 
stored at 4 °C. 
Transferrin Isolation from Blood Plasma 
Tf was isolated from 70 or 100 μL of human plasma pool, 
ψ(sample, 1 × PBS, pH 7.4) = 1 : 7 or 1 : 9 using peristaltic 
pump (flow rate of 0.5 mL min–1 or 1 mL min–1) or vacuum 
manifold, in case when CIMac-@Tf column or CIMac-@Tf 
96-well plate were used for isolation, respectively. 
 The CIMac-@Tf column was washed with 1 mL of  
0.1 mol L–1 formic acid, pH 3.0 or 3.5 [pH is adjusted with 
ammonia solution (φ = 25 %), fraction F1] and 2 mL of 1 × 
PBS, pH 7.4. Diluted plasma sample was applied to the 
column and column was washed with 6 mL of 1 × PBS, pH 7.4 
(fractions W1–W6). Tf was eluted with 1 mL of 0.1 mol L–1 
formic acid, pH 3.0 or 3.5 (fractions of 0.5 mL were 
collected, E1–E2). The CIMac-@Tf column was additionally 
washed with 1 mL of 0.1 mol L–1 formic acid, pH 3.0 or 3.5 
(fraction E3), 1 mL of 0.1 mol L–1 formic acid, pH 2.5 
(fractions of 0.5 mL were collected, E4–E5), 3 mL of 1 × PBS, 
pH 7.4 (fractions P1–P3) and 2 mL of storage buffer (1 × PBS, 
pH 7.4, 0.2 g L–1 NaN3). All acidic fractions were neutralized 
with 1 mol L–1 ammonium hydrogencarbonate to pH 7.0. 
Each elution or washing fraction (300 μL or 500 μL) was 
dried in a vacuum centrifuge for subsequent glycan 
analysis. 
 CIMac-@Tf 96-well plate was used in a similar way, 
with following differences: plate was equilibrated with 4 mL 
of 1 × PBS, pH 7.4 (instead of 2 mL) before sample 
application, Tf was eluted from the plate with 0.1 mol L–1 
formic acid, pH 3.0, and plate was washed with 4 mL of 1 × 
PBS, pH 7.4 (instead of 3 mL), before washing with storage 
buffer. 
 The CIMac-@Tf column and the CIMac-@Tf 96-well 
plate were stored at 4 °C. All sample fractions were stored 
at –20 °C. 
 Elution fractions were analyzed by SDS-PAGE using 
4–12 % Bis-Tris gradient gels (1.0 mm thickness) under 
reducing conditions according to the manufacturer's 
instructions (Life Technologies). The gels were run at 200 V 
for 35 min using a MES SDS buffering system. Protein bands 
were visualized by GelCode Blue staining reagent. 
Desalting of Tf Samples Before 
Deglycosylation 
Dried Tf eluates were desalted by adding 1 mL of cold 
methanol (previously cooled down to –20 °C). Samples were 
resuspended with a pipette and centrifuged for 15 minutes 
at 2200 g with adhesive seal (Eppendorf centrifuge, model 
5804). Supernatant (970 μL) was carefully removed and 
procedure was repeated. Remaining methanol was removed 
by drying desalted samples in the vacuum centrifuge. 
N-Glycan Release and Labeling 
The whole procedure was done in a 96-well plate manner 
and ultra-pure water was used throughout. Dried Tf eluates 
were denatured with 30 μL of SDS (γ = 13.3 g L–1) and by 
incubation at 65 °C for 10 min. After cooling down to room 
temperature for 30 min, 10 μL of Igepal CA-630 (φ = 4 %) 
was added and mixture was shaken for 15 min on a plate 
shaker. N-glycans were released after addition of 1.2 U of 
PNGase F in 10 μL of 5 × PBS by incubation at 37 °C for 18 
hours. Released N-glycans were labeled with 2-AB. The 
labeling mixture was freshly prepared by dissolving 2-AB 
(final γ = 19.2 mg mL–1) and 2-PB (final γ = 44.8 mg mL–1) in 
the mixture of DMSO and glacial acetic acid, ψ(DMSO, 
CH3COOH) = 7 : 3. To each of the N-glycan samples 25 μL of 
the labeling mixture was added and the plate was sealed 
using an adhesive seal. Mixing was achieved by 10 min 
shaking, followed by 2 hour incubation at 65 °C.  
Clean-Up of 2-AB Labeled Glycans 
Free 2-AB label, excess of reagents and proteins were 
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labeling using hydrophilic interaction liquid chromatography 
solid phase extraction (HILIC-SPE). After cooling down to 
room temperature for 30 min, 700 μL of acetonitrile 
(previously cooled down to 4 °C) was added to each sample. 
The clean-up procedure was performed on a hydrophilic  
0.2 μm AcroPrep GHP filter plate. Solvent was removed by 
vacuum manifold at around 25 mm Hg. All wells were 
prewashed with 200 μL of ethanol in water (φ = 70 %),  
200 μL of ultra-pure water and 200 μL of acetonitrile in water 
(φ = 96 %, previously cooled down to 4 °C). The samples 
diluted with cold acetonitrile were loaded to the wells, and 
after short incubation subsequently washed with 5 × 200 μL 
of acetonitrile in water (φ = 96 %, previously cooled down to 
4 °C). Glycans were eluted with 2 × 90 μL of ultra-pure water 
after 15 min shaking at room temperature and combined 
eluates were stored at –20 °C until the UPLC analysis.  
Glycan Analysis by Ultra Performance 
Liquid Chromatography 
Fluorescently labeled and purified N-glycans were separated 
by HILIC-UPLC and detected using excitation and emission 
wavelengths of 250 and 428 nm, respectively. The instrument 
was under the control of Empower 3 software, build 3471 
(Waters). The 2-AB labeled N-glycans were separated on a 
Waters BEH Glycan chromatography column, 150 × 2.1 mm 
i.d., 1.7 μm BEH particles, with 100 mmol L–1 ammonium 
formate, pH 4.4, as solvent A and acetonitrile as solvent B. 
The 2-AB labeled glycan samples were prepared in 
acetonitrile, ψ(sample, acetonitrile) = 25 : 75, and analyzed in 
linear gradient of 30–47 % solvent A at flow rate of 0.56 mL 
min–1 in a 23 min analytical run. Samples were maintained at 
10 °C before injection onto the column, and the column 
temperature was 25 °C. The HILIC-UPLC system was 
calibrated using an external standard of hydrolyzed and 2-AB 
labeled glucose oligomers (dextran ladder) according to 
which the retention times for the individual chromatographic 
peaks (representing the 2-AB labeled glycan) were converted 
to glucose units. Data processing was performed using an 
automatic processing method with a traditional integration 
algorithm. Furthermore, each chromatogram was manually 
corrected to maintain the same intervals of integration for all 
the samples. The samples were all separated into 35 peaks and 
the amount of glycans in each chromatographic peak was 
expressed as percentage of total integrated area (% Area). 
 
RESULTS AND DISCUSSION 
Chromatographic Characterization of 
Monolithic Columns and a 96-Well Plate 
for Tf Isolation 
The CIMac-@Tf columns were successfully prepared 
according to procedure developed for immobilization of 
polyclonal antibody specific for human serum albumin[27] 
using a mAb specific for transferrin (@Tf) and a hydrazide 
column, as described in the paragraph Preparation of 
columns with immobilized @Tf. After antibody immobi-
lization, we confirmed that the column is specific for Tf. 
Since the final application for the prepared columns is 
isolation of the protein from plasma sample, we evaluated 
the column's specificity using a HPLC system and 1 mL of 10 
times diluted plasma sample in bind / elute mode. In order 
to test the column efficiency at high-throughput conditions, 
we used a high flow rate of 1.0 mL min–1. The bound 
proteins were eluted using 0.1 mol L–1 of formic acid, pH 2.4 
(Figure 1). The analysis of collected fractions by SDS-PAGE 
showed that the purity of the elution fraction was above  
95 % (Figure 1, insert). The Tf was eluted from the column 
in 500 µL of elution buffer, corresponding to 5 column 
volumes. However, the CIMac-@Tf column started 
deteriorating with the consecutive bind-elute runs and 
therefore the optimization of elution buffer was 
performed. The initial formic acid elution buffer was 
partially neutralized with NaOH to pH values of 3.5 and 3.0. 
A large elution peak was observed at pH 3.5, and after 
changing the medium to pH 3.0 an additional elution peak 
was observed, but it comprised less than 0.5 % of total area 
(results not shown). Although total elution of Tf was 
achieved even with 0.1 mol L–1 formic acid, pH 3.5, pH 3.0 
was selected for further experiments in order to avoid 
possible cross-contamination between separate isolations. 
Additionally, Na+ ions are incompatible with downstream 
analysis of Tf glycosylation and thus the final elution buffer 
was pH adjusted using NH3. After the initial protocol was 
established, the column was tested with 5 consecutive 
 
Figure 1. Black line: typical HPLC-UV profile of plasma 
loading and elution from CIMac-@Tf column. Red line: 
elution of bound proteins with 0.1 mol L–1 formic acid, pH 
2.4. Insert: SDS-PAGE gel of Tf standard and Tf isolated from 
human plasma in the 1st and 4th consecutive isolations on 
the same column. Lanes: (1) 10–200 kDa molecular mass 
standard (Fermentas Life Sciences, Burlington, Canada); (2)
standard human Tf (0.1 mg mL–1); (3) Tf elution from the 1st
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bind-elute experiments and no deterioration of the column 
was observed anymore. 
 To confirm the stability of the CIMac-@Tf column 
and complete elution of bound Tf, fractions collected 
during Tf isolation have been analyzed by SDS-PAGE (not 
shown). Additionally, HILIC-UPLC glycan analysis was 
performed for all fractions since it can detect antibody 
leakage in the washing steps after column storage or during 
Tf isolation procedure (Figure 2). There was no detectable 
antibody leakage during the washing step before sample 
application (fraction F1, Figure 2) and the majority of the 
bound Tf eluted from the column in the first 0.5 mL of  
0.1 mol L–1 formic acid, pH 3.0 (fraction E1, Figure 2). 
 Initial amount of Tf is important for reproducible 
glycosylation analysis by HILIC-UPLC and around 300 μg of 
purified Tf is required from a single capture step from blood 
plasma. Therefore, the binding capacity for pure Tf 
dissolved in PBS buffer was determined for prototype 
CIMac-@Tf columns. The DBC50 values were between 3.5 
and 3.9 mg of Tf per mL of monolithic support, enabling 
isolation of more than 300 μg of Tf in a single run using  
0.1 mL CIMac-@Tf column. 
 High-throughput method development is essential 
for fast analysis of Tf glycosylation in large number of 
samples. For parallel isolation of Tf from 96 plasma samples 
we prepared a 96-well plate with immobilized @Tf as 
described in Experimental section. Since large-pores 
monoliths have higher permeability and consequently 
decreased possibility of clogging and higher throughput, we 
used 2.1 μm average pore size diameter monoliths for 
CIMac-@Tf 96 well plate preparation, compared to 1.4 μm 
average pore size diameter monoliths used for CIMac-@Tf 
columns. On the other hand, large pores decrease the 
surface area of the monolith and result in decreased 
binding capacity for antigen,[28] so monoliths of larger 
volume (200 μL) were used for CIMac-@Tf 96-well plate, 
compared to the monoliths used for the column format 
(100 μL). After @Tf immobilization the CIMac-@Tf 96-well 
plate was characterized for pure human Tf binding capacity 
with the same reagents as with the CIMac-@Tf columns. 
There was no difference in absorbance between effluent 
fractions and PBS buffer at 280 nm (before each column 
was saturated), proving complete binding of Tf and no 
leakage of @Tf. After complete Tf saturation of the 
immunoaffinity sorbent, the plate was washed with PBS 
buffer, followed by protein elution and quantification. The 
average amount of eluted Tf calculated from absorbance 
reading at 280 nm was 300 µg per well with relative 
standard deviation (RSD) of 9.1 % for the whole plate, what 
is comparable with commercially available CIM® protein G 
or protein A 96-well plates. The Tf elution capacity was 
within previously determined requirements for amount of 
purified Tf and newly prepared CIMac-@Tf 96-well plate 
could be used for larger population studies. 
Optimization of Tf Isolation and Glycan 
Preparation 
Tf N-glycome typically contains only 5–6 high abundant  
(> 2 % of the total N-glycome each) N-glycans (Figure 3). 
Since low abundant peaks generally have higher 
coefficients of variation, we tried to improve the sensitivity 
of quantification by optimizing the conditions for Tf 
isolation and glycan preparation before the UPLC analysis. 
Originally, after isolation from blood plasma Tf was eluted 
from CIMac-@Tf 96-well plate in 1 mL of 0.1 mol L–1 formic 
acid, pH 3.0 and 300 μL of eluate was dried and 
 
Figure 2. Glycosylation profiles of fractions collected during 
Tf isolation from human blood plasma on CIMac-@Tf 
column. F1 – wash with 1 mL of 0.1 mol L–1 formic acid, pH 
3.0 (pH adjusted with ammonia solution, φ = 25 %) before 
plasma sample application; E1, E2 – Tf elution fractions with 
1 mL of 0.1 mol L–1 formic acid, pH 3.0 (0.5 mL each); E3 –
additional wash with 1 mL of 0.1 mol L–1 formic acid, pH 3.0; 
E4, E5 – additional wash with 1 mL of 0.1 mol L–1 formic acid, 
pH 2.5 (0.5 mL each); P1 – wash with 1 mL of 1x PBS, pH 7.4. 
EU – emission units. 
 
 
Figure 3. Representative HILIC-UPLC chromatogram of Tf 
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deglycosylated as described in Experimental section. After 
clean-up, 2-AB labeled glycans are typically eluted from 
hydrophilic GHP filter plate in 2 × 90 μL of ultra-pure water. 
We tested different elution volumes during transferrin 
isolation (1 mL and 0.7 mL) and the volume of transferrin 
eluate used for deglycosylation (300 μL and 500 μL). Since 
an extensive amount of salts in protein sample can affect 
reaction yields, we desalted isolated transferrin with 
methanol. In order to get even more concentrated sample, 
we tested different conditions for glycan elution from GHP 
filter plate (Table 1). Each experiment was performed in 
four replicates with the same plasma sample. 
 Several tested combinations of preparation condi-
tions (volume of elution fraction during Tf isolation, volume 
of Tf eluate used for deglycosylation, desalting with 
methanol, and volume of ultra-pure water used for glycan 
elution from GHP plate after clean-up procedure) gave 
significantly improved intensities of glycan peaks in HILIC-
UPLC chromatogram (around 250 EU) compared to 
previously used standard preparation conditions described 
in the previous paragraph (around 50 EU, dark grey in 
Figure 4). Desalting with methanol was shown to be 
somewhat challenging to perform, and could lead to 
sample losses in methanol removing steps. Due to these 
reasons desalting with methanol was excluded from the 
final protocol for Tf glycan analysis. However, in the 
absence of methanol desalting step, we observed that for 
Tf samples that contained a higher amount of salts 
(ammonium formate) and proteins, we had to add more 
than 100 μL of ultra-pure water for the glycan elution in 
order to obtain sufficient glycans recovery from GHP filter 
plate after clean-up procedure. In contrast to that, all 
samples that have previously been desalted with methanol, 
showed very good glycan recovery even when only 50 μL of 
ultra-pure water was used for glycan elution from GHP filter 
plate. Also, by increasing the volume of ultra-pure water for 
glycan elution, signal intesities were getting lower due to 
decreasing glycan concentration in eluates, which is 
expected, but is only noticed in samples that have been 
desalted with methanol, and in samples that have not been 
desalted with methanol but contained the lowest amount 
of salts and proteins (Figure 4). This phenomenon has 
already been noticed in HILIC chromatography and is 
explained by suppresion of negatively charged sialic acids 
repulsion by presence of salts in mobile phase, which in 
result allows tighter binding of sialylated glycans to the 
water-enriched solvent layer on the surface of the 
stationary phase.[29] Additionaly, we noticed that 
chromatographic profiles of Tf glycans were different 
depending whether samples were desalted with methanol 
before deglycosylation or not. Since transferrin contains 
mostly sialylated N-glycans, this mechanism obviously plays 
a significant role in glycan clean-up step. 
 In order to be able to assess the variability of the 
method, following experimental conditions were further 
tested with larger number of samples (n = 24 for each):  
(i) transferrin elution from monolithic support with 1 mL of 
formic acid, drying and deglycosylation of 300 μL of eluate, 
glycan elution in 2 × 25 μL of ultra-pure water, (ii) transferrin 
elution from monolithic support with 1 mL of formic acid, 
drying and deglycosylation of 500 μL of eluate, glycan 
elution in 2 × 50 μL of ultra-pure water, (iii) transferrin 
elution from monolithic support with 0.7 mL of formic acid, 
drying and deglycosylation of 300 μL of eluate, glycan 
elution in 2 × 50 μL of ultra-pure water (Table 1). 
 
Table 1. Optimization of transferrin isolation and glycan 
preparation conditions. 
Velution(a) /  
mL  
Vdried(b) /  
μL  
Desalted with  
MeOH  





2 × 25  
1 × 50  
2 × 50  
2 × 90  
NO 
2 × 25  
1 × 50  
2 × 50  
2 × 90  
500 
YES 
2 × 25  
1 × 50  
2 × 50  
2 × 90  
NO 
2 × 25  
1 × 50  
2 × 50  
2 × 90  
0.7 300 
YES 
2 × 25  
1 × 50  
2 × 50  
2 × 90  
NO 
2 × 25  
1 × 50  
2 × 50  
2 × 90  
(a) Velution – volume of elution fraction during Tf isolation. 
(b) Vdried – volume of Tf eluate used for deglycosylation. 
(c) Vglycan eluate – volume of ultra-pure water used for glycan elution from GHP 
plate after clean-up procedure.  
Each experiment was performed in four replicates from the same initial 
plasma sample. Grey shaded combinations of experimental conditions are 
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 Transferrin elution from monolithic support with  
0.7 mL of formic acid, followed by drying and deglycosylation 
of 300 μL of eluate and glycan elution in 2 × 50 μL of ultra-
pure water, gave the most reproducible results. The peak 
percent area CVs were < 5 % for 12 peaks, 5–10 % for 13 
peaks, 10–15 % for 4 peaks, and > 15 % for 6 peaks, compared 
to the other two tested combinations where only 4 out of 35 
glycan peaks had CVs < 5 % (see Table 2). 
 IgG N-glycome is known to share some N-glycans with 
Tf N-glycome. Indeed, chromatograms of some the samples 
showed that small amount of IgG was co-purified with Tf. In 
addition, concentrated elution fraction samples analysed by 
SDS-PAGE contained additional bands when IgG was not 
removed from plasma sample before transferrin isolation 
(Figure 5). In order to eliminate the possible contamination 
and skewing of the results, we removed the IgG from initial 
plasma sample before the Tf isolation. Therefore, we suggest 
to use IgG depleted plasma for Tf isolation when UPLC is used 
for glycan quantification. Improved Tf purification (without 
visible IgG bands after fractions analysis by SDS-PAGE) was 
also achieved if 1 × PBS, pH 7.4 with increased NaCl 
 
 
Figure 4. Optimization of transferrin isolation and glycan 
preparation conditions, according to Table 1. Previously 
used standard preparation conditions are shown in dark 
grey. White – dry Tf eluate samples were desalted with cold 
methanol before deglycosylation. Grey – dry Tf eluate 
samples were not desalted before deglycosylation. Average 
value and standard deviation of highest glycan peak 
intensity are shown, as well as the mass of protein used 
(n = 4). EU – emission unit. 
 
 
Figure 5. SDS-PAGE of 5× concentrated elution fractions 
after transferrin isolation from IgG depleted plasma (lanes 1 
and 2) and plasma without IgG depletion (lanes 3 and 4). 
M – Precision Plus ProteinTM Standards All Blue molecular 
mass standard (Bio-Rad). Arrows represent bands from 
contaminants in case when IgG was not removed from 
blood plasma before Tf isolation. 
 
Table 2. Coefficients of variation (CV) of glycan 
chromatographic peak percent areas in relation to 
experimental conditions from Table 1 tested on larger 
number of samples (n = 24). 
Peak percent area CV / % 
Number of peaks 
A B C 
0–5  4  4  12  
5–10  13  13  13  
10–15  15  4  4  
> 15  3  14  6  
Experimental conditions (see Table 1): A − Velution = 1 mL of 0.1 mol L–1 formic 
acid, pH 3.0, Vdried = 300 μL, Vglycan eluate = 2× 25 μL of ultra-pure water. 
B – Velution = 1 mL of 0.1 mol L–1 formic acid, pH 3.0, Vdried = 500 μL, Vglycan eluate
= 2× 50 μL of ultra-pure water. C − Velution = 0.7 mL of 0.1 mol L–1 formic acid, 
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concentration (250 mmol L–1 instead of 137 mmol L–1) was 




Here we describe for the first time a preparation and 
application of CIMac-@Tf 96-well monolithic plate for 
immunoaffinity purification of Tf. First, a successful 
technological transfer of the @Tf mAb immobilization from a 
single monolithic column to the plate format was 
accomplished. Next, the purification conditions for Tf 
isolation from human plasma were optimized together with 
the subsequent N-glycan preparation method., Thus, we 
obtained a clean sample that allowed highly sensitive HILIC-
UPLC quantification of Tf N-glycans. The established method 
enables high-throughput Tf isolation. In the future, we plan 
to isolate Tf from up to one thousand blood plasma samples 
and analyze Tf N-glycans to assess the natural biological 
variability of Tf N-glycome of healthy individuals as well as to 
detect disease caused changes of the Tf N-glycome. 
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